Abivax Gets Positive FDA Feedback, Stays on Track to File for New Ulcerative Colitis Drug by End of 2026

Abivax completes positive pre-NDA meeting with FDA for obefazimod in ulcerative colitis, stays on track for 2026 filing, with $3-5B peak sales potential.